{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:51:45Z","timestamp":1791082305991,"version":"4.1.0"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Cutaneous lupus erythematosus (CLE) is a highly heterogeneous autoimmune disease. No specific Federal Drug Administration-approved therapies for CLE-alone are available, and resistance to conventional treatments is common. This review will summarize current treatment approaches and pending treatment strategies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Research into the pathogenesis of CLE is accelerating. A skewed type I interferon production and response contribute to CLE lesions. The pathophysiology of lesions may be similar among the lesional subtypes, and patients with a more TLR9-driven disease mechanism may have more benefit from hydroxychloroquine. Case reports continue to support the use of dapsone for CLE, especially bullous lupus erythematosus. Rituximab and Belimumab have efficacy in patients with systemic lupus erythematosus and severe active CLE. The significant role for type I interferons in CLE and encouraging clinical data suggest anifrolumab as a very promising agent for CLE. Dapirolizumab, BIIB059, Ustekinumab and Janus kinase inhibitors also have supportive early data as promising new strategies for CLE treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Continued research to understand the mechanisms driving CLE will facilitate the development and approval of new targets. The pipeline for new treatments is rich.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000704","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T12:41:03Z","timestamp":1583498463000},"page":"208-214","source":"Crossref","is-referenced-by-count":43,"title":["Treatment of cutaneous lupus erythematosus: current approaches and future strategies"],"prefix":"10.1097","volume":"32","author":[{"given":"Hong","family":"Shi","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann E.","family":"Gudjonsson","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Michelle","family":"Kahlenberg","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230829","article-title":"Chronic cutaneous lupus erythematosus (discoid lupus) induced by palbociclib","author":"Freedman","year":"2019","journal-title":"Int J Dermatol"},{"key":"R2-20230829","doi-asserted-by":"crossref","DOI":"10.5070\/D32510045821","article-title":"Widespread subacute cutaneous lupus erythematosus in a patient receiving checkpoint inhibitor immunotherapy with ipilimumab and nivolumab","volume":"25","author":"Kosche","year":"2019","journal-title":"Dermatol Online J"},{"key":"R3-20230829","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/jdv.14053","article-title":"S2k guideline for treatment of cutaneous lupus erythematosus \u2013 guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)","volume":"31","author":"Kuhn","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R4-20230829","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.autrev.2012.08.019","article-title":"Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE)","volume":"12","author":"Biazar","year":"2013","journal-title":"Autoimmun Rev"},{"key":"R5-20230829","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1136\/annrheumdis-2018-213197","article-title":"Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa","volume":"77","author":"Sarkar","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R6-20230829","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.4049\/jimmunol.1800650","article-title":"Hypersensitive IFN responses in lupus keratinocytes reveal key mechanistic determinants in cutaneous lupus","volume":"202","author":"Tsoi","year":"2019","journal-title":"J Immunol"},{"key":"R7-20230829","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8081244","article-title":"Molecular profiling of cutaneous lupus lesions identifies subgroups distinct from clinical phenotypes","volume":"8","author":"Berthier","year":"2019","journal-title":"J Clin Med"},{"key":"R8-20230829","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1001\/jama.2019.5586","article-title":"Effect of sunscreen application under maximal use conditions on plasma concentration of sunscreen active ingredients: a randomized clinical trial","volume":"321","author":"Matta","year":"2019","journal-title":"JAMA"},{"key":"R9-20230829","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R10-20230829","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.berh.2013.07.008","article-title":"Cutaneous lupus erythematosus: diagnosis and treatment","volume":"27","author":"Okon","year":"2013","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R11-20230829","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2147\/TCRM.S3193","article-title":"Topical calcineurin inhibitors in systemic lupus erythematosus","volume":"6","author":"Lampropoulos","year":"2010","journal-title":"Ther Clin Risk Manag"},{"key":"R12-20230829","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2147\/CCID.S184824","article-title":"Current insights into the management of discoid lupus erythematosus","volume":"12","author":"Company-Quiroga","year":"2019","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"R13-20230829","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.semarthrit.2019.07.010","article-title":"Management of cutaneous manifestations of lupus erythematosus: a systematic review","volume":"50","author":"Fairley","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"R14-20230829","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5070\/D30R49C68V","article-title":"Two cases of refractory discoid lupus erythematosus successfully treated with topical tocoretinate","volume":"17","author":"Terao","year":"2011","journal-title":"Dermatol Online J"},{"key":"R15-20230829","first-page":"226728","article-title":"Chronic cutaneous lupus erythematosus and topical clindamycin","author":"Newman","year":"2018","journal-title":"BMJ Case Rep"},{"key":"R16-20230829","doi-asserted-by":"crossref","first-page":"e0164080","DOI":"10.1371\/journal.pone.0164080","article-title":"JAK3 as an emerging target for topical treatment of inflammatory skin diseases","volume":"11","author":"Alves de Medeiros","year":"2016","journal-title":"PLoS One"},{"key":"R17-20230829","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/bjd.15312","article-title":"Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis","volume":"177","author":"Chasset","year":"2017","journal-title":"Br J Dermatol"},{"key":"R18-20230829","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jaad.2019.07.027","article-title":"An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: a systematic review","volume":"82","author":"Shipman","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R19-20230829","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/1346-8138.14802","article-title":"Varied responses to and efficacies of hydroxychloroquine treatment according to cutaneous lupus erythematosus subtypes in Japanese patients","volume":"46","author":"Ototake","year":"2019","journal-title":"J Dermatol"},{"key":"R20-20230829","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3389\/fimmu.2019.00275","article-title":"Effect of in vivo hydroxychloroquine and ex vivo anti-BDCA2 mAb treatment on pDC IFN\u03b1 production from patients affected with cutaneous lupus erythematosus","volume":"10","author":"Gardet","year":"2019","journal-title":"Front Immunol"},{"key":"R21-20230829","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","article-title":"Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision)","volume":"123","author":"Marmor","year":"2016","journal-title":"Ophthalmology"},{"key":"R22-20230829","article-title":"Retinal complications in systemic lupus erythematosus patients treated with antimalarial drugs","author":"Mukwikwi","year":"2019","journal-title":"J Rheumatol"},{"key":"R23-20230829","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/art.41121","article-title":"Hydroxychloroquine blood levels predict hydroxychloroquine retinopathy","volume":"72","author":"Petri","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R24-20230829","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jaad.2017.09.061","article-title":"Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: a retrospective cohort study","volume":"78","author":"Mittal","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R25-20230829","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jaad.2015.09.064","article-title":"The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): an open-label prospective pilot study","volume":"74","author":"Chasset","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"R26-20230829","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","article-title":"The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy","volume":"132","author":"Melles","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"R27-20230829","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jaad.2017.08.045","article-title":"Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: a multicenter observational study","volume":"78","author":"Chasset","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R28-20230829","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/rheumatology\/key434","article-title":"Dapsone: an old drug effective for subacute cutaneous lupus erythematosus","volume":"58","author":"Zampeli","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"R29-20230829","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.semarthrit.2017.11.003","article-title":"Clinical, histological, immunological presentations and outcomes of bullous systemic lupus erythematosus: 10 new cases and a literature review of 118 cases","volume":"48","author":"de Risi-Pugliese","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"R30-20230829","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jaad.2017.09.059","article-title":"Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: a systematic review and meta-analysis","volume":"78","author":"Chasset","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R31-20230829","article-title":"Thalidomide and Lenalidomide for refractory systemic\/cutaneous lupus erythematosus treatment: a narrative review of literature for clinical practice","author":"Yuki","year":"2019","journal-title":"J Clin Rheumatol"},{"key":"R32-20230829","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/annrheumdis-2017-212916","article-title":"Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus","volume":"77","author":"Schafer","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"(Suppl 10)","key":"R33-20230829","article-title":"A randomized, placebo-controlled, double-blind, ascending-dose, safety, and pharmacokinetics study of CC-220 in subjects with systemic LUPUS erythematosus [abstract]","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R34-20230829","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41584-019-0272-0","article-title":"Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies","volume":"15","author":"Wenzel","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"R35-20230829","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.autrev.2018.02.011","article-title":"The 2018 pipeline of targeted therapies under clinical development for systemic lupus erythematosus: a systematic review of trials","volume":"17","author":"Felten","year":"2018","journal-title":"Autoimmun Rev"},{"key":"R36-20230829","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.semarthrit.2014.04.002","article-title":"Efficacy and safety of rituximab in the treatment of nonrenal systemic lupus erythematosus: a systematic review","volume":"44","author":"Cobo-Ibanez","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"R37-20230829","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/art.39085","article-title":"Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus","volume":"67","author":"Vital","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R38-20230829","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1001\/jamadermatol.2018.3793","article-title":"Sara-cino AM. Assessment of response to B-cell depletion using rituximab in cutaneous lupus erythematosus","volume":"154","author":"Quelhas da Costa","year":"2018","journal-title":"JAMA Dermatol"},{"key":"R39-20230829","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1136\/annrheumdis-2011-200831","article-title":"Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials","volume":"71","author":"Manzi","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R40-20230829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2017.09.004","article-title":"Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study","volume":"86","author":"Iaccarino","year":"2018","journal-title":"J Autoimmun"},{"key":"R41-20230829","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/1744666X.2017.1324784","article-title":"When to use belimumab in SLE","volume":"13","author":"Gatto","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"R42-20230829","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1080\/14712598.2018.1513484","article-title":"Novel biological therapeutic approaches to cutaneous lupus erythematosus","volume":"18","author":"Tayer-Shifman","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"R44-20230829","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.kint.2018.08.025","article-title":"A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int"},{"key":"R45-20230829","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1172\/JCI124466","article-title":"Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus","volume":"129","author":"Furie","year":"2019","journal-title":"J Clin Invest"},{"key":"R47-20230829","doi-asserted-by":"crossref","first-page":"e000284","DOI":"10.1136\/lupus-2018-000284","article-title":"Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus","volume":"5","author":"Merrill","year":"2018","journal-title":"Lupus Sci Med"},{"key":"R48-20230829","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"issue":"(Suppl 10)","key":"R49-20230829","article-title":"PK\/PD, safety and exploratory efficacy of subcutaneous anifrolumab in SLE: a phase-II study in interferon type I high patients with active skin disease [abstract]","volume":"71","author":"Bruce","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R50-20230829","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/art.40052","article-title":"Brief report: pharmacodynamics, safety, and clinical efficacy of amg 811, a human antiinterferon-\u03b3 antibody, in patients with discoid lupus erythematosus","volume":"69","author":"Werth","year":"2017","journal-title":"Arthritis Rheum"},{"key":"R51-20230829","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"key":"R52-20230829","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1001\/jamadermatol.2018.5077","article-title":"Assessment of clinical response to janus kinase inhibition in patients with familial chilblain lupus and TREX1 mutation","volume":"155","author":"Zimmermann","year":"2019","journal-title":"JAMA Dermatol"},{"key":"R53-20230829","article-title":"Efficacy of baricitinib on refractory skin papulosquamous rash in a patient with systemic lupus erythematosus","author":"Fornaro","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"R54-20230829","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/annrheumdis-2019-215455","article-title":"Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre","volume":"78","author":"You","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R57-20230829","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","article-title":"Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study","volume":"392","author":"van Vollenhoven","year":"2018","journal-title":"Lancet"},{"key":"R58-20230829","article-title":"Maintenance of efficacy and safety of ustekinumab through 1 year in a randomized phase II trial of patients with active systemic lupus erythematosus","author":"van Vollenhoven","year":"2019","journal-title":"Arthritis Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000704","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T07:10:23Z","timestamp":1693293023000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000704","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}